Solid Tumors
📧 Sign up to get email alerts when something new happens for Solid Tumors.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-06-23Clinical Trial Update: Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors [Phase 1]
Phase 1 study of DS-8201a in subjects with advanced solid malignant tumors has completed enrollment with results posted.
-
CLINICAL_TRIALS trial_result · 2021-06-14Clinical Trial Update: NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b) [Phase 2]
Phase 2 study results for NKTR-102 in combination with cetuximab in refractory solid tumors and metastatic/locally advanced colorectal cance…
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) [Phase 1, Phase 2]
A phase 1/2 study of E7050 in combination with E7080 in advanced solid tumors and specific recurrent/unresectable cancers; the trial status …
-
CLINICAL_TRIALS trial_result · 2021-06-04Clinical Trial Update: A Study of Atezolizumab in Advanced Solid Tumors [Phase 2]
Phase 2 trial update of atezolizumab in advanced solid tumors with results posted.
-
CLINICAL_TRIALS trial_result · 2021-05-20Clinical Trial Update: Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors [Phase 1]
Phase 1b trial evaluating lenvatinib plus pembrolizumab in selected solid tumors has completed with posted results.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-05-13Clinical Trial Update: A Phase 1/2 Study to Evaluate MEDI4736 [Phase 1, Phase 2]
Phase 1/2 study update for MEDI4736 (durvalumab) in advanced solid tumors; completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-05-13Clinical Trial Update: Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors [Phase 1]
Phase 1 multicenter study of PM060184 in combination with gemcitabine in selected patients with advanced solid tumors completed; results pos…
-
CLINICAL_TRIALS trial_result · 2021-05-13Clinical Trial Update: Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation [Phase 2]
A Phase 2 clinical trial evaluating arsenic trioxide in patients with refractory solid tumors possessing rescuable p53 mutations.
-
CLINICAL_TRIALS trial_result · 2021-04-23Clinical Trial Update: Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial evaluating safety, tolerability, and immunoregulatory activity of mogamulizumab (KW-0761) in patients with advanced or metas…
-
CLINICAL_TRIALS trial_result · 2021-04-22Clinical Trial Update: K-BASKET, TAS-117, PI3K/AKT Gene Aberration [Phase 2]
Phase 2 clinical trial update (K-BASKET) evaluating TAS-117 targeting PI3K/AKT gene aberrations in solid tumors completed.
-
CLINICAL_TRIALS trial_result · 2021-04-08Clinical Trial Update: Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010) [Phase 2]
Phase 2 extension study update for EC145 (Vintafolide) in subjects from a previous MK-8109-010 study; study status is completed.
-
CLINICAL_TRIALS trial_result · 2021-03-01Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors [Phase 2]
Phase 2 study evaluating cobimetinib plus atezolizumab in solid tumors has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-02-25Clinical Trial Update: An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) [Phase 1]
Phase 1 open-label pharmacokinetics and safety study of talazoparib (MDV3800) in advanced solid tumors has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers [Phase 2]
A Phase II trial evaluating nivolumab in patients with DNA damage repair gene alterations who progressed after standard treatment for metast…
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors [Phase 1]
First-in-human Phase 1 study of IBI308 in Chinese subjects with advanced solid tumors has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) [Phase 2]
Open-label extension study of Conatumumab and Ganitumab (AMG 479) in a Phase 2 trial for advanced solid tumors; completed with results poste…
-
CLINICAL_TRIALS trial_result · 2021-02-17Clinical Trial Update: An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols [Phase 1, Phase 2]
An extension protocol update for subjects previously enrolled in other tivantinib (ARQ 197) protocols across Phase 1 and Phase 2 trials; stu…
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations [Phase 1, Phase 2]
Pilot trial of BMN 673 (olaparib) in advanced solid tumors with deleterious BRCA mutations completed phases 1 and 2; results posted.
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure. [Phase 1]
Phase I dose-escalation study of efavirenz in solid tumors and non-Hodgkin lymphoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-01-14Clinical Trial Update: Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors [Phase 1, Phase 2]
Phase 1/2 dose-escalation trial evaluating birinapant with pembrolizumab in solid tumors; study terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2021-01-07Clinical Trial Update: FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
An early-phase trial evaluating EVER4010001, an FGFR4 inhibitor, in combination with pembrolizumab for advanced solid tumors is in Phase 1/P…
-
CLINICAL_TRIALS trial_result · 2020-12-29Clinical Trial Update: A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203) [Phase 1, Phase 2]
Phase 1/2 study of epacadostat plus durvalumab in selected advanced solid tumors completed; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-12-29Clinical Trial Update: Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer [Phase 1]
Phase 1 study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of alobresib (GS-5829) in adults with advanced solid t…
-
CLINICAL_TRIALS trial_result · 2020-12-29Clinical Trial Update: A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid Tumors [Phase 1]
Phase 1 trial assessing relative bioavailability, food effect, and gastric pH modification on TAK-931 pharmacokinetics in participants with …
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression [Phase 1, Phase 2]
Phase 1/2 study of FGF401 in hepatocellular carcinoma and other solid tumors characterized by FGFR4 and KLB expression has completed. Result…